IP Library Granted Patent US 11,998,609
Granted Patent B2
US 11,998,609 · App. 17/981,595 · Granted Jun 4, 2024

Self-assembling antiviral prodrugs

Inventors: Honggang Cui (Baltimore, MD); Charles Williams Flexner (Baltimore, MD); Maya Monroe (Baltimore, MD); Han Wang (Baltimore, MD)
Assignee: The Johns Hopkins University
A61K47/64A61P31/18A61P31/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,998,609
App. No.
17/981,595
Granted
Jun 4, 2024
Kind
B2
Abstract

Disclosed are therapeutic self-assembling molecules including a peptide sequence conjugated to one or more antiviral therapeutics to form a peptide-based antiviral prodrug capable of self-assembly into supramolecular structures with varying morphology in aqueous solutions, which can be injected subcutaneously or intramuscularly for the long-acting treatment of chronic viral infections.

Claims (8)

1. A composition comprising a peptide-based antiretroviral therapeutic (ARV) prodrug selected from the group consisting of:

2. The composition of claim 1 , wherein the composition further comprises a hydrophobic moiety encapsulated within a hydrophobic core of the composition.

3. A method for treating a viral infection in a subject in need thereof, wherein the method comprises administering to said subject a therapeutically effective amount of a composition of claim 1 , and wherein said viral infection is selected from a retroviral infection or a hepatitis B viral infection.

4. The method of claim 3 , wherein said viral infection is a chronic viral infection.

5. The method of claim 3 , wherein said viral infection is a hepatitis B viral infection.

6. The method of claim 3 , wherein said viral infection is a human immunodeficiency virus (HIV) infection.

7. The method of claim 3 , wherein the composition is administered by subcutaneous or intramuscular injection.

8. The method of claim 3 , wherein the subject has a hepatitis B viral infection or acquired immune deficiency syndrome (AIDS).

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 12, 2025
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 070189/0071 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2022
From: CUI, HONGGANG; FLEXNER, CHARLES WILLIAMS; MONROE, MAYA; WANG, HAN
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 061851/0179 →
Continuity (2)
Provisional Application 63277144 · Nov 8, 2021
Related Publication 20230147365A1 · May 11, 2023